Zenas BioPharma reported a Q3 net loss Wednesday of $1.22 per diluted share, narrower than a loss of $5.02 a year earlier.
Three analysts surveyed by FactSet expected a loss of $0.83.
As of Sept. 30, the company said it had $301.6 million in cash, cash equivalents, and investments, which along with $120 million raised from a private placement in October is expected to fund operations and capital expenditures through Q4 of 2026.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments